Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC105 and Sorafenib in HCC
NCT02560779Phase 2Completed
- Sponsor
- TRACON Pharmaceuticals, Inc.
- Start
- Nov 2016
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of carotuximab in hepatocellular carcinoma (HCC), sponsored by TRACON Pharmaceuticals, Inc.. Started Nov 2016; status: completed.
02
Drugs
carotuximab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02560779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560779.